107 related articles for article (PubMed ID: 30178381)
1. Role of CXCR4 Antagonist in Megakaryocyte Reinstatement with Increased Sinusoidal Vessel Density.
Lee JY; Han AR; Hwang HS; Kim DC; Min WS; Kim HJ
Adv Exp Med Biol; 2018; 1072():419-422. PubMed ID: 30178381
[TBL] [Abstract][Full Text] [Related]
2. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.
Nervi B; Ramirez P; Rettig MP; Uy GL; Holt MS; Ritchey JK; Prior JL; Piwnica-Worms D; Bridger G; Ley TJ; DiPersio JF
Blood; 2009 Jun; 113(24):6206-14. PubMed ID: 19050309
[TBL] [Abstract][Full Text] [Related]
4. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
[TBL] [Abstract][Full Text] [Related]
5. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
Tavor S; Petit I
Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
7. Targeting the bone marrow microenvironment in acute leukemia.
Karantanou C; Godavarthy PS; Krause DS
Leuk Lymphoma; 2018 Nov; 59(11):2535-2545. PubMed ID: 29431560
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
[TBL] [Abstract][Full Text] [Related]
9. AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds.
Shen ZH; Zeng DF; Kong PY; Ma YY; Zhang X
Blood Cells Mol Dis; 2016 Jul; 59():16-24. PubMed ID: 27282562
[TBL] [Abstract][Full Text] [Related]
10. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
Bernasconi P; Farina M; Boni M; Dambruoso I; Calvello C
Am J Hematol; 2016 May; 91(5):507-17. PubMed ID: 26822317
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic alteration of bone marrow HSC and microenvironmental association in experimentally induced leukemia.
Basak P; Chatterjee S; Das M; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
Curr Stem Cell Res Ther; 2010 Dec; 5(4):379-86. PubMed ID: 20528754
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
Cooper TM; Sison EAR; Baker SD; Li L; Ahmed A; Trippett T; Gore L; Macy ME; Narendran A; August K; Absalon MJ; Boklan J; Pollard J; Magoon D; Brown PA
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28409853
[TBL] [Abstract][Full Text] [Related]
14. In and out of the niche: perspectives in mobilization of hematopoietic stem cells.
Mohty M; Ho AD
Exp Hematol; 2011 Jul; 39(7):723-9. PubMed ID: 21624427
[TBL] [Abstract][Full Text] [Related]
15. A novel CXCR4 antagonist for hematopoietic stem cell mobilization.
Fricker SP
Expert Opin Investig Drugs; 2008 Nov; 17(11):1749-60. PubMed ID: 18922110
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin K cleavage of SDF-1α inhibits its chemotactic activity towards glioblastoma stem-like cells.
Hira VV; Verbovšek U; Breznik B; Srdič M; Novinec M; Kakar H; Wormer J; der Swaan BV; Lenarčič B; Juliano L; Mehta S; Van Noorden CJ; Lah TT
Biochim Biophys Acta Mol Cell Res; 2017 Mar; 1864(3):594-603. PubMed ID: 28040478
[TBL] [Abstract][Full Text] [Related]
17. [Some research progress of CXCR4 antagonist AMD3100].
Chang CK; Zhang X; Zhao YS; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):831-4. PubMed ID: 21729582
[TBL] [Abstract][Full Text] [Related]
18. Influence of Bone Marrow Microenvironment on Leukemic Stem Cells: Breaking Up an Intimate Relationship.
Agarwal P; Bhatia R
Adv Cancer Res; 2015; 127():227-52. PubMed ID: 26093902
[TBL] [Abstract][Full Text] [Related]
19. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 antagonist delivery on decellularized skin scaffold facilitates impaired wound healing in diabetic mice by increasing expression of SDF-1 and enhancing migration of CXCR4-positive cells.
Liu H; Liu H; Deng X; Chen M; Han X; Yan W; Wang N
Wound Repair Regen; 2017 Aug; 25(4):652-664. PubMed ID: 28783870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
